In the rapidly evolving life sciences landscape, where the pursuit of innovative therapies and life-saving drugs never ceases, science and technology are increasingly playing a vital role. High-performance Computing (HPC) stands at the forefront of this technology revolution, empowering pharmaceutical and medical device enterprises, as well as research and academia, to unravel the complexities of biology, medicine, and multi-omics like never before.
HPC is no longer confined to successful pilot phases but is transitioning to wider adoption, addressing essential business needs across industries, including life sciences. The pharmaceutical industry, dealing with vast volumes of complex and heterogenous data, is an ideal sector for harnessing the benefits of HPC – particularly around intricate biological interactions, complex data analysis, and sophisticated simulations.
In this viewpoint, we study HPC’s high-potential use cases in life sciences and how pharmaceutical companies can derive success from their HPC initiatives.
In this report, we explore: